Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

Core Viewpoint - Vincerx Pharma, Inc. is set to delist its common stock from Nasdaq due to non-compliance with listing rules, with trading suspended and plans for liquidation announced [2][3][4]. Group 1: Delisting and Trading Suspension - Vincerx received a delisting notice from Nasdaq on April 14, 2025, due to its common stock closing bid price being below the minimum requirement of $1.00 per share for 30 consecutive business days [2]. - Trading of Vincerx's common stock will be suspended at the opening of business on April 23, 2025, and the company intends to file a Form 25 Notification of Delisting with the SEC around April 28, 2025 [1][2]. - An inadvertent suspension of trading occurred on April 16, 2025, but trading will resume on April 21, 2025, until April 22, 2025 [4]. Group 2: Company Actions and Future Plans - The board of directors has decided to dissolve, liquidate, and wind up the company's affairs, distributing any remaining assets to stockholders after settling debts [3]. - Vincerx does not plan to appeal Nasdaq's determination and will not seek to list its common stock on another exchange [3]. - Following the effectiveness of Form 25, Vincerx will file a Form 15 to deregister with the SEC [4]. Group 3: Company Background - Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, with a research facility in Monheim, Germany [5].